A Phase 3, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Ropeginterferon Alfa-2b in Patients with Moderate COVID-19Wang-Da Liu, Wang‐Huei Sheng, Weichung Joe Shih et al.|Infectious Diseases and Therapy|2024Cited by 0
Nirmatrelvir-ritonavir significantly reduces severe COVID-19 outcomes in diverse Taiwanese populations: Comprehensive evidence from a large-scale longitudinal cohort study in TaiwanFu‐Der Wang, Jason C. Hsu, Mei-Hui Lee et al.|Journal of Infection and Public Health|2025Cited by 0